Serum ANCA and Overall Mortality: A 10-Year Retrospective Cohort Study on 1,024 Italian Subjects

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Sep 27

PMID 34566970

Authors

Enrico Brunetta

Giacomo Ramponi

Marco Folci

Maria De Santis

Emanuela Morenghi

Elena Vanni

Elena Bredi

Raffaello Furlan

Claudio Angelini

Carlo Selmi

Affiliations

Soon will be listed here.

Abstract

Background: Antineutrophil cytoplasmic antibodies (ANCA) are primarily involved in the pathogenesis of ANCA-associated vasculitides (AAV). However, ANCA may also be present in healthy subjects and in patients with autoimmune disorders different from AAV. We hypothesized that serum ANCA are associated with a worse prognosis in disorders other than AAV.

Objective: We investigated the association between the overall survival and the presence of serum ANCA in 1,024 Italian subjects with various testing indications in a 10-year interval.

Methods: In this retrospective cohort study, a population of 6,285 patients (many of whom were subsequently excluded due to our criteria) who tested for ANCA at a single center in 10 years was considered, and life status and comorbidities of subjects were collected. We compared the overall survival of ANCA-positive and ANCA-negative patients by means of Kaplan-Meier curves, while a multivariable adjusted Cox regression was used to evaluate the association between the ANCA status and the outcome (death) in terms of hazard ratios (HR) with 95% confidence intervals (CI).

Results: The positivity of perinuclear ANCA (pANCA) increased significantly mortality (HR, 1.60; 95% CI, 1.10-2.32), while cytoplasmic ANCA (cANCA) positivity failed to show a significant association (HR, 1.43; 95% CI, 0.77-2.68). The increased mortality rate was observed for both pANCA and cANCA in patients suffering from rheumatic disorders. No association was found between mortality and anti-MPO (HR, 0.63; 95% CI, 0.20-2.00) or anti-PR3 (HR, 0.98; 95% CI, 0.24-3.96) after adjusting for confounders.

Conclusions: Serum pANCA and cANCA are independent negative prognostic factors in patients with concurrent autoimmune diseases.

References

McLaren J, Stimson R, McRorie E, Coia J, Luqmani R . The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. QJM. 2001; 94(11):615-21. DOI: 10.1093/qjmed/94.11.615. View

Xiao H, Heeringa P, Liu Z, Huugen D, Hu P, Maeda N . The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol. 2005; 167(1):39-45. PMC: 1603451. DOI: 10.1016/S0002-9440(10)62951-3. View

Lee K, Kronbichler A, Park D, Park Y, Moon H, Kim H . Neutrophil extracellular traps (NETs) in autoimmune diseases: A comprehensive review. Autoimmun Rev. 2017; 16(11):1160-1173. DOI: 10.1016/j.autrev.2017.09.012. View

Damoiseaux J, Csernok E, Rasmussen N, Moosig F, van Paassen P, Baslund B . Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis. 2016; 76(4):647-653. DOI: 10.1136/annrheumdis-2016-209507. View

Tsiveriotis K, Tsirogianni A, Pipi E, Soufleros K, Papasteriades C . Antineutrophil cytoplasmic antibodies testing in a large cohort of unselected greek patients. Autoimmune Dis. 2011; 2011:626495. PMC: 3112505. DOI: 10.4061/2011/626495. View

Villanueva E, Yalavarthi S, Berthier C, Hodgin J, Khandpur R, Lin A . Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011; 187(1):538-52. PMC: 3119769. DOI: 10.4049/jimmunol.1100450. View

Sinico R, Radice A . Antineutrophil cytoplasmic antibodies (ANCA) testing: detection methods and clinical application. Clin Exp Rheumatol. 2014; 32(3 Suppl 82):S112-7. View

Radice A, Bianchi L, Maggiore U, Vaglio A, Sinico R . Comparison of PR3-ANCA specific assay performance for the diagnosis of granulomatosis with polyangiitis (Wegener's). Clin Chem Lab Med. 2013; 51(11):2141-9. DOI: 10.1515/cclm-2013-0308. View

Berglin E, Mohammad A, Dahlqvist J, Johansson L, Eriksson C, Sjowall J . Anti-neutrophil cytoplasmic antibodies predate symptom onset of ANCA-associated vasculitis. A case-control study. J Autoimmun. 2020; 117:102579. DOI: 10.1016/j.jaut.2020.102579. View

10.

Roth A, Ooi J, Hess J, van Timmeren M, Berg E, Poulton C . Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013; 123(4):1773-83. PMC: 3613913. DOI: 10.1172/JCI65292. View

11.

Vittecoq O, Jouen-Beades F, Krzanowska K, Menard J, Daragon A, Gilbert D . Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis. Rheumatology (Oxford). 2000; 39(5):481-9. DOI: 10.1093/rheumatology/39.5.481. View

12.

Sonel Tur B, Suldur N, Ataman S, Tutkak H, Atay M, Duzgun N . Anti-neutrophil cytoplasmic antibodies in patients with rheumatoid arthritis: clinical, biological, and radiological correlations. Joint Bone Spine. 2004; 71(3):198-202. DOI: 10.1016/j.jbspin.2003.04.002. View

13.

Stone J, Merkel P, Spiera R, Seo P, Langford C, Hoffman G . Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363(3):221-32. PMC: 3137658. DOI: 10.1056/NEJMoa0909905. View

14.

Ramponi G, Folci M, De Santis M, Damoiseaux J, Selmi C, Brunetta E . The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies. Autoimmun Rev. 2021; 20(3):102759. DOI: 10.1016/j.autrev.2021.102759. View

15.

Mahr A, Batteux F, Tubiana S, Goulvestre C, Wolff M, Papo T . Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol. 2014; 66(6):1672-7. DOI: 10.1002/art.38389. View

16.

Bosch X, Guilabert A, Font J . Antineutrophil cytoplasmic antibodies. Lancet. 2006; 368(9533):404-18. DOI: 10.1016/S0140-6736(06)69114-9. View

17.

Watts R, Lane S, SCOTT D, Koldingsnes W, Nossent H, Gonzalez-Gay M . Epidemiology of vasculitis in Europe. Ann Rheum Dis. 2002; 60(12):1156-7. PMC: 1753455. DOI: 10.1136/ard.60.12.1156a. View

18.

Jennette J, Falk R, Andrassy K, Bacon P, Churg J, Gross W . Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994; 37(2):187-92. DOI: 10.1002/art.1780370206. View

19.

Gregersen J, Erikstrup C, Ivarsen P, Glerup R, Krarup E, Keller K . PR3-ANCA-associated vasculitis is associated with a specific motif in the peptide-binding cleft of HLA-DP molecules. Rheumatology (Oxford). 2019; 58(11):1942-1949. DOI: 10.1093/rheumatology/kez111. View

20.

Gomez-Puerta J, Bosch X . Anti-neutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update. Am J Pathol. 2009; 175(5):1790-8. PMC: 2774045. DOI: 10.2353/ajpath.2009.090533. View